Study on the Therapeutic Effect of TCM Treatment for MDR MN

NCT02610595 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2015-11-20

No results posted yet for this study

Summary

To evaluate the effectiveness and safety of the Chinese medicine treatment for multiple drug resistance of MN patients with Jianpiyiqi and Huoxuejiedu Recipe.

Conditions

  • Idiopathic Membranous Nephropathy

Interventions

DRUG

Jianpixiaozhong particles and Wuse Dietotherapy

Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER
  • Ruijin Hospital

    collaborator OTHER
  • Shanghai 6th People's Hospital

    collaborator OTHER
  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER
  • Changhai Hospital

    collaborator OTHER
  • Shanghai Putuo District Center Hospital

    collaborator OTHER
  • ShuGuang Hospital

    collaborator OTHER
  • Shanghai Yueyang Integrated Medicine Hospital

    collaborator OTHER
  • Shanghai Changzheng Hospital

    collaborator OTHER
  • Shanghai Minhang Central Hospital

    collaborator OTHER
  • Zhujiang Hospital

    collaborator OTHER
  • Guangxi Traditional Chinese Medical University

    collaborator OTHER
  • Huashan Hospital

    collaborator OTHER
  • The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

    collaborator OTHER
  • Xinqiao Hospital of Chongqing

    collaborator OTHER
  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    collaborator OTHER
  • Nanjing University of Traditional Chinese Medicine

    collaborator OTHER
  • Tongji Hospital

    collaborator OTHER
  • Chinese Academy of Sciences

    collaborator OTHER_GOV
  • RenJi Hospital

    collaborator OTHER
  • Shanghai University of Traditional Chinese Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02610595 on ClinicalTrials.gov